Viracta Therapeutics, Inc. (VIRX)
OTCMKTS
· Delayed Price · Currency is USD
0.0250
+0.0021 (9.17%)
Mar 31, 2025, 11:04 AM EST
Viracta Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
932.00K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
Viracta Therapeutics News
- 7 weeks ago - Viracta Therapeutics Announces Wind Down of Operations - GlobeNewsWire
- 3 months ago - Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - GlobeNewsWire
- 4 months ago - Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 8 months ago - Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 8 months ago - Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - GlobeNewsWire
- 11 months ago - Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 11 months ago - Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - GlobeNewsWire
- 11 months ago - Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire